ConductScience.org, home

Comparison · NCT01968317-4e546353

Megestrol Acetate and Metformin vs Megestrol Acetate: Pregnancy Rate

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Megestrol Acetate and Metformin vs Megestrol Acetate: Pregnancy Rate. Trial comparisons, record NCT01968317-4e546353. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01968317-4e546353

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5140.3590.666wilson
Risk in group 20.4840.320.652wilson
Risk difference, group 1 minus group 20.0296-0.1980.253newcombe hybrid score
Risk ratio, group 1 over group 21.060.6571.72log
Odds ratio, group 1 over group 21.130.4332.93log
Number needed to treat, for one more participant with the outcome on Megestrol Acetate and Metformin than on Megestrol Acetate33.7from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Megestrol Acetate and Metformin
Patients will receive metformin 500 mg by mouth three times daily and megestrol acetate 160 mg by mouth daily. Hysteroscopic evaluation was performed every 3 months during the therapy to evaluate the endometrial condition, and the findings will be recorded.
1937OG000
Group 2Megestrol Acetate
Patients will receive megestrol acetate 160 mg by mouth daily. Hysteroscopic evaluation was performed every 3 months during the therapy to evaluate the endometrial condition, and the findings will be recorded.
1531OG001

Outcome

Type
SECONDARY
Title
Pregnancy Rate
Description
All patients were followed up till February 2019. The pregnancy rate was calculated only in women who planned for parenthood immediately after achieving CR.
Time frame
through study completion, a median time of 33 months
Population
In MA+metformin group only 31 cases wanted to have a baby, and that in MA group were 37.

Source ClinicalTrials.gov

Trial

Title
Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
NCT number
NCT01968317
Phases
PHASE2
Conditions
Endometrial Atypical Hyperplasia, Endometrial Adenocarcinoma
Interventions
Megestrol acetate and metformin, Megestrol acetate
Lead sponsor
Xiaojun Chen
Results first posted
2021-09-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01968317-4e546353